Built for better biologics. Developability-first antibody technology platform

We combine advanced mammalian display with rapid iteration to generate higher-quality antibody leads. Our platform enables the identification of sequence liability-minimized, functional and biophysically favorable antibodies, including complex bispecific formats. Standardized workflows and rigorous science are built in. Partnering models include platform licensing and co-development.

…and let’s talk about your molecule.

What is Evogence Biologics?

Evogence Biologics is a Finnish biotechnology start-up developing proprietary antibody discovery and engineering technologies for biopharma. Our core expertise is an enhanced mammalian display platform developed and optimized through years of research and development. The platform identifies high-quality, functional antibodies with strong developability profiles. We collaborate with partners through platform licensing and co-development.

Our guiding principles:

Open, transparent and trustworthy communication

Partners get clear communication and milestone visibility.

Scientific expertise and quality

Building developability-first antibody discovery technology using cutting-edge methods and data-driven decision-making.

Data and IP security

We ensure partner data is stored securely and partners retain full ownership of their data.

Platform capabilities

Our mammalian display platform and antibody engineering workflows support diverse discovery and optimization programs. Capability areas include antibody discovery, advanced engineering, and bispecific antibody discovery. We collaborate with biopharma partners through platform licensing and co-development.

We combine sequence liability-minimized phage display libraries with a mammalian display platform to identify potent antibody candidates that meet predefined functional and developability criteria.

We have a proven track record and years of experience in antibody engineering and maturation. We improve functional and biophysical properties across challenging antibody formats, including multispecific molecules.

Our platform supports bi- and multispecific discovery with in-format selection and functional screening. A dedicated workflow accelerates the generation of complex bispecific and multispecific antibodies.

Why our mammalian display stands out

Pre-selection of binders using liability-minimized phage display libraries.

Mammalian display screening to select hits with exceptional developability i.e. high affinity, good expression, high stability and low aggregation propensity.

AI-powered in silico developability assessment that supports manufacturability evaluation and reduces CMC risk.

For bispecifics, final re-formatting, mammalian display selection and functional screening to confirm robust functional activity in the final format.

Pre-selection of binders using liability-minimized phage display libraries.

Mammalian display screening to select hits with exceptional developability i.e. high affinity, good expression, high stability and low aggregation propensity.

AI-powered in-silico assessment that assures good manufacturability and de-risks development and CMC.

For bispecifics, final re-formatting, mammalian display selection and functional screening to confirm robust functional activity in the final format.

Pre-selection of binders using liability-minimized phage display libraries.

Mammalian display screening to select hits with exceptional developability i.e. high affinity, good expression, high stability and low aggregation propensity.

AI-powered in-silico assessment that assures good manufacturability and de-risks development and CMC.

For bispecifics, final re-formatting, mammalian display selection and functional screening to confirm robust functional activity in the final format.